Viatris, Inc.

As of August 25, 2025, Viatris, Inc. is in a mildly bearish trend, indicated by daily moving averages and a bearish monthly MACD, while underperforming the S&P 500 with year-to-date and one-year returns of -20.80% and -17.14%, respectively.

As of May 9, 2024, Viatris, Inc. is considered overvalued with a P/E ratio of 38, low returns on equity and capital, and significant underperformance compared to the S&P 500, leading to a valuation grade shift from expensive to risky.

As of May 9, 2024, Viatris, Inc. is considered risky and overvalued with a P/E ratio of 38, low returns on equity and capital, and a negative year-to-date return of -28.92%, significantly underperforming compared to its peers and the S&P 500.

As of May 27, 2025, Viatris, Inc. shows a mildly bearish trend due to daily moving averages and monthly Bollinger Bands, despite some mildly bullish signals from the weekly MACD and KST, with overall sentiment dampened by weak RSI signals and underperformance against the S&P 500.

Viatris, Inc. is a mid-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $3.24 billion and a net profit of -$3.04 billion. Key metrics include a P/E ratio of 38.00, a dividend yield of 123.82%, and a market cap of approximately $10.5 billion.

As of Jun 18, Viatris, Inc. has a market capitalization of $10.50 billion, with recent net sales of $14.26 billion and a net profit of -$3.79 billion.